Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared <i>KRAS</i> and <i>TP53</i> mutations expressed by solid tumors in first-in-human phase 1 study.Maria Pia Morelli, Scott Kopetz, Nathan Demars et al.|Journal of Clinical Oncology|2023Cited by 12
First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.Marcelo V. Negrão, Scott Kopetz, Maria Pia Morelli et al.|Journal of Clinical Oncology|2022Cited by 3